15.11
Modelos farmacodinámicos: modelo lineal de concentración-efecto
El modelo lineal de concentración-efecto, basado en el principio de que el efecto farmacológico (E) es directamente proporcional a la concentración pl…
El modelo lineal concentración-efecto asume que el efecto farmacológico, E, es directamente proporcional a la concentración plasmática del fármaco, C. p.
Al representar la concentración plasmática de fármacos frente a un efecto, la curva concentración-efecto es aproximadamente lineal por debajo de EC50.
El modelo plantea que el efecto del fármaco aumenta continuamente con el aumento de las concentraciones hasta alcanzar el efecto farmacológico máximo, Emax.
Sin embargo, esta relación lineal no se cumple en un amplio rango de concentraciones.
A pesar de estas limitaciones, el modelo se utiliza ampliamente para evaluar los efectos de los fármacos sobre la repolarización cardíaca, medidos por el intervalo QT en un electrocardiograma o ECG.
Por ejemplo, bajo este modelo, el gráfico entre la concentración de moxifloxacina y la prolongación del intervalo QTc da lugar a una curva lineal.
Además, la relación concentración-QTc desempeña un papel clave en la evaluación regulatoria de la FDA de nuevos medicamentos para evaluar el riesgo proarrítmico.
View the full transcript and gain access to JoVE Core videos
Q1: What is the linear concentration-effect model in pharmacodynamics?
The linear concentration-effect model assumes that pharmacological effect (E) is directly proportional to plasma drug concentration (Cp). This model simplifies the Emax model when drug concentrations are significantly below the EC50 threshold. The concentration-effect curve appears approximately linear in this range, with drug effect increasing continuously until reaching maximum pharmacological effect (Emax).
Q2: When is the linear concentration-effect model applicable?
The linear concentration-effect model applies when plasma drug concentrations are markedly below the EC50 threshold, where the relationship between concentration and effect remains approximately linear. However, this linearity does not hold across wide concentration ranges, limiting the model's applicability to comprehensive pharmacodynamic modeling. It is most useful for evaluating specific drug effects within restricted concentration windows.
Q3: How is the linear concentration-effect model used in cardiac safety assessment?
The linear concentration-effect model is widely used to evaluate drug effects on cardiac repolarization, measured by the QT interval on an electrocardiogram (ECG). For example, the plot between moxifloxacin concentration and QTc interval prolongation yields a linear curve. This concentration-QTc relationship plays a key role in the FDA's regulatory evaluation of new drugs for assessing proarrhythmic risk.
Q4: What are the limitations of the linear concentration-effect model?
The linear concentration-effect model assumes continuous effect augmentation with increasing drug concentrations, but this assumption does not hold across extensive concentration ranges. The model's linearity is restricted to conditions where concentrations remain significantly below EC50. These inherent limitations confine its applicability to specific pharmacodynamic scenarios rather than comprehensive drug effect modeling.
Q5: How does the linear model relate to the Emax model?
The linear concentration-effect model emerges as a pivotal simplification of the Emax model for conditions where plasma drug concentration is significantly less than EC50. Under these restricted conditions, the nonlinear Emax relationship approximates a linear trajectory. This simplification allows for straightforward analysis while maintaining accuracy within the applicable concentration range.
Q6: Why is the concentration-QTc relationship important for drug development?
The concentration-QTc relationship facilitates the US FDA's regulatory review processes, particularly in assessing proarrhythmic risks associated with novel therapeutic agents. This analysis has been extensively applied in characterizing moxifloxacin and developing new pharmacological entities. The linear model's utility in this context underscores its significance in advancing drug safety evaluations during regulatory approval.
Q7: What does EC50 represent in the linear concentration-effect model?
EC50 represents the plasma drug concentration at which 50% of the maximum pharmacological effect is achieved. The linear concentration-effect model applies when actual drug concentrations remain significantly below this EC50 threshold. Above EC50, the linear relationship breaks down and the model's assumptions no longer hold, requiring alternative pharmacodynamic models for accurate predictions.